Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The CONKO-001 study of adjuvant gemcitabine for resected pancreatic cancer by Dr Oettle and colleagues1 reported improved disease-free survival with the addition of chemotherapy compared with observation. The total rate of local recurrences in this study was approximately 40% in both groups, which appears low when compared with other published data. Local recurrence was a component of failure in 62% of all recurrences in the ESPAC-1 trial, which included 69 patients who also received no adjuvant therapy following surgery.2
Shivnani AT. Adjuvant Chemotherapy With Gemcitabine for Patients With Resectable Pancreatic Cancer. JAMA. 2007;297(23):2581-2582. doi:10.1001/jama.297.23.2581-b